iBio, Inc. (IBIO)
Designs AI-powered antibodies to treat cancer, obesity, and heart disease.
$1.41-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+113.7%
The outlook
iBio is trading well below both its 50- and 200-day moving averages, sitting near the lower end of its 52-week range. Analyst coverage leans bullish on price targets—the average sits roughly 283% above the current price—but the stock's near-term momentum and overall score remain weak. The disconnect between near-term technicals and longer-term analyst targets reflects elevated uncertainty.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range26% of the way from its 52-week low to high
Price targetAvg target +283% vs current price
Analyst price target
~12-month · 8 analysts$5.40average target+282.8% vs now
Now $1.41
Low $4.20High $7.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$70.1M
52-wk high
$3.82
52-wk low
$0.56
50-day avg
$1.63
200-day avg
$1.81
Trailing P/E
—